| pubmed-article:7949100 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C0007586 | lld:lifeskim |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C0209660 | lld:lifeskim |
| pubmed-article:7949100 | lifeskim:mentions | umls-concept:C2828360 | lld:lifeskim |
| pubmed-article:7949100 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:7949100 | pubmed:dateCreated | 1994-12-20 | lld:pubmed |
| pubmed-article:7949100 | pubmed:abstractText | Leukemic B cells from a majority of patients with chronic lymphocytic leukemia (CLL) enter the cell cycle upon stimulation in vitro with loxoribine, a potent 7,8-disubstituted guanine ribonucleoside immunostimulant. In the absence of added costimulants, a proportion of these cells become activated and undergo DNA synthesis and mitosis accompanied by a marked increase in expression of an array of cell surface activation antigens. The resultant activated B-CLL cells exhibit greatly enhanced sensitivity to cycle-active cytotoxic drugs. This approach may be of potential value in the therapy of CLL. | lld:pubmed |
| pubmed-article:7949100 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7949100 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7949100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7949100 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7949100 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7949100 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:7949100 | pubmed:author | pubmed-author:GoodmanM GMG | lld:pubmed |
| pubmed-article:7949100 | pubmed:author | pubmed-author:WormsleyS BSB | lld:pubmed |
| pubmed-article:7949100 | pubmed:author | pubmed-author:PiroL DLD | lld:pubmed |
| pubmed-article:7949100 | pubmed:author | pubmed-author:SpinosaJ CJC | lld:pubmed |
| pubmed-article:7949100 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7949100 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:7949100 | pubmed:volume | 84 | lld:pubmed |
| pubmed-article:7949100 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7949100 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7949100 | pubmed:pagination | 3457-64 | lld:pubmed |
| pubmed-article:7949100 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:meshHeading | pubmed-meshheading:7949100-... | lld:pubmed |
| pubmed-article:7949100 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7949100 | pubmed:articleTitle | Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. | lld:pubmed |
| pubmed-article:7949100 | pubmed:affiliation | Department of Immunology, Scripps Research Institute, La Jolla, CA. | lld:pubmed |
| pubmed-article:7949100 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7949100 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7949100 | lld:pubmed |
